Galderma’s Announcement Regarding NEMLUVIO (EC Approval for the Treatment of Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis)

TOKYO, February 17, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on February 14 that they have received approval from the European Commission for NEMLUVIO ® (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. Nemolizumab was created by Chugai, and its clinical development and marketing outside Japan is being conducted by Galderma. Please refer to the link below for details of the Galderma’s press release: Galderma’s Nemluvio ® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis https://www.galderma.com/news/galdermas-nemluvior-nemolizumab-approved-european-union-moderate-severe-atopic-dermatitis-and Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗